Alexander Cumbo
Patrimonio netto: 2 M $ in data 30/06/2026
Patrimonio netto: 2 M $ in data 30/06/2026
Mr. Alexander G.
Cumbo is an Independent Director at Vor Biopharma, Inc., an Independent Director at Climb Bio, Inc. and a President, Chief Executive Officer & Director at Solid Biosciences, Inc. He is on the Board of Directors at Vor Biopharma, Inc., Climb Bio, Inc. and Solid Biosciences, Inc. Mr. Cumbo was previously employed as an Independent Director by Verve Therapeutics, Inc., a President, Chief Executive Officer & Director by AavantiBio, Inc., an Independent Director by RA Pharmaceuticals, Inc., a Chief Commercial Officer & Executive VP by Sarepta Therapeutics, Inc., and a Vice President-Sales & Treatment Education by Vertex Pharmaceuticals, Inc. He also served on the board at Clinical Supplies Management, Inc. He received his undergraduate degree from Auburn University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 235.405 ( 0,24% ) | 2 M $ | 30/06/2026 | |
CLIMB BIO, INC. -.--% | 05/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
VOR BIOPHARMA, INC. -.--% | 11/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SOLID BIOSCIENCES INC. | Amministratore Delegato | 02/12/2022 |
| CLIMB BIO, INC. | Direttore/Membro del Consiglio | 28/03/2025 |
| VOR BIOPHARMA INC. | Direttore/Membro del Consiglio | 16/07/2025 |
| Società | Posizione | Fine |
|---|---|---|
| VERE THER | Direttore/Membro del Consiglio | 25/07/2025 |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Amministratore Delegato | 01/12/2022 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2020 |
| RA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 02/04/2020 |
Clinical Supplies Management, Inc.
Clinical Supplies Management, Inc. Medical/Nursing ServicesHealth Services Offers clinical trial services to biotechnology and pharmaceutical companies | Direttore/Membro del Consiglio | 01/01/2017 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Auburn University
Auburn University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clinical Supplies Management, Inc.
Clinical Supplies Management, Inc. Medical/Nursing ServicesHealth Services Offers clinical trial services to biotechnology and pharmaceutical companies | Health Services |
Solid Biosciences, Inc.
Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
Vor Biopharma, Inc.
Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Verve Therapeutics, Inc.
Verve Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat patients with cardiovascular disease | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale